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Abstract: The aim of the study was to investigate ultrasound tissue characterization of carotid plaques
in subjects with and without diabetes type 1 (T1D). B-mode carotid ultrasound was performed to
assess the presence and type of plaque in a group of 340 subjects with and 304 without T1D, all of
them without cardiovascular disease. One hundred and seven patients with T1D (49.5% women;
age 54 ± 9.8 years) and 67 control subjects without diabetes who had at least one carotid plaque
were included in the study. The proportion of subjects who had only echolucent plaques was
reduced in the group of patients with T1D (48.6% vs. 73.1%). In contrast, the proportion with only
echogenic (25.2% vs. 7.5%) and calcified plaques (9.4% vs. 1.5%) was increased compared with
subjects without diabetes. Moreover, having at least one echogenic plaque was more frequent in T1D
patients compared with subjects without diabetes (49.5% vs. 26.9% p = 0.005). In addition to diabetes
(OR 2.28; p = 0.026), age (OR 1.06, p = 0.002) was the other variable associated with echogenic plaque
existence in multiple regression analysis. Patients with T1D exhibit a differential pattern of carotid
plaque type compared with subjects without diabetes, with an increased frequency of echogenic and
extensively calcified plaques.
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1. Introduction
Atherosclerotic cardiovascular disease (CV) is a major cause of mortality in patients with type 1
diabetes [1,2]. Its main clinical manifestations include myocardial infarction, stroke and peripheral
vascular disease. The common nexus of this group of cardiovascular events is atherosclerosis, which
is characterized as a chronic lipid deposition process in the sub-endothelial space that develops
insidiously throughout life and is typically in an advanced stage when its symptoms manifest clinically
in the form of a cardiovascular event.
Ultrasonography is a non-invasive, safe, reproducible and well-validated method for visualizing
and quantifying atherosclerotic lesions [3]. The presence and burden of subclinical carotid
atherosclerotic plaque is strongly associated with future arterial CV events [4,5]. A high prevalence
of carotid plaques has been described in patients with type 2 diabetes without evidence of clinical
CV disease [6]. Data regarding atherosclerotic plaques in patients with type 1 diabetes are very
scarce. In this sense, our group has recently described an increased proportion and burden of carotid
plaques in a group of 340 patients with T1D without CV events compared with a group of subjects
without diabetes [7]. On the other hand, plaque echogenicity as assessed by carotid ultrasound reliably
predicts the content of soft tissue and the amount of calcification in carotid plaques [8]. In this regard,
echolucent plaques exhibit more lipid, inflammatory cells and haemorrhage compared with echogenic
plaques, which contain more calcification and fibrous tissue; characteristics that have been validated by
histopathology [8–10]. Otherwise, calcified plaques in the coronary arteries determined by computed
tomography scanning coronary artery calcium (CAC) are accepted as a measure of CV disease burden
both in patients with [11] and without diabetes [4]. Vascular calcification beyond coronary arteries (i.e.,
carotid and aortic plaques) has also been described to be associated with all-cause and CV mortality
both in patients with [12] and without type 2 diabetes [13].
Studies that have evaluated plaques characteristics by carotid ultrasonography demonstrated
that lipid rich plaques (echolucent) are associated with an increased risk of CV events in patients
with symptomatic stenotic (≥50%) plaques [14,15]. Most studies that have analyzed the presence
and ultrasound characteristics of carotid plaques in patients with diabetes have been performed in
asymptomatic subjects with T2D. In these patients both echolucent [16,17] and echogenic [18] plaques
were shown to be associated with an increased risk of future CV events. Data regarding subclinical
atherosclerotic plaques characteristics assessed by carotid ultrasound in patients with type 1 diabetes
are lacking. To our knowledge, no studies to date have analyzed plaque characteristics by carotid
ultrasound in patients with type 1 diabetes.
The present study aimed to analyze ultrasound non-stenotic carotid plaque echogenicity in a
group of patients with type 1 diabetes and to compare the results obtained with a group of subjects
without diabetes, all of whom do not have previous history of clinical CV disease and exhibit normal
renal function.
2. Experimental Section
2.1. Subjects
This study is a sub-analysis of a previous study from our research group [7]. From that study,
174 subjects with at least one atherosclerotic plaque, including 107 patients with type 1 diabetes
and 67 without diabetes, were selected. Our previous study was a cross-sectional study conducted
in 340 patients with type 1 diabetes and 304 subjects without diabetes matched by sex and age.
All participants were free from previous CV disease. Subjects with type 1 diabetes were recruited from
the diabetic outpatient clinics at University Hospital Germans Trias i Pujol and University Hospital
Arnau de Vilanova in the north-western region of Spain (Catalonia). All potential participants were
identified from the electronic clinical records from the two participating institutions that belong to the
same health care organization.
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For type 1 diabetic subjects, the inclusion criteria were as follows: age >18 years; diabetes for
at least 1 year; normal renal function (estimated glomerular filtration rate (eGFR >60 mL/min));
no previous CV disease defined as any form of clinical coronary heart disease, stroke or peripheral
vascular disease (including any form of diabetic foot disease). Moreover, we excluded patients with a
urine albumin excretion ratio >300 mg/g. The selection of subjects without diabetes was based on the
same criteria, except for the criteria that concerned the diabetic specific microvascular complications.
Additionally, subjects in the control group had fasting glucose and HbA1c values less than 100 mg/dL
and 5.7% (39 mmol/mol), respectively.
For each subject, age, sex, body mass index and waist circumference were obtained by
standardized methods. Subjects were considered to have hypertension or dyslipidaemia if they
were under anti-hypertensive or lipid-lowering agent treatment, respectively. Serum and spot urine
samples were collected in the fasting state, and all serum and urine tests were performed using
standard laboratory methods as previously described [19].
2.2. Carotid Ultrasound Imaging
The detailed protocol used to evaluate the presence of carotid plaques by ultrasound has been
previously described [19]. Briefly, carotid ultrasonography imaging was performed using a LOGIQ® E9
(General Electric, Wauwatosa, WI, USA) equipped with a 15-MHz linear array probe or a Sequoia 512
(Siemens, North Rhine, Westphalia, Germany) equipped with a 15-MHz linear array probe. Plaques
were identified using B-mode and colour Doppler examinations in both the longitudinal and transverse
planes to consider circumferential asymmetry and were defined as a “focal structure that encroaches
into the arterial lumen of at least 0.5 mm or 50% of the surrounding carotid intima media thickness
value or demonstrates a thickness of 1.5 mm, as measured from the media-adventitia interference
to the intima-lumen surface” according to the Mannheim consensus [20]. Further, the LOGIQ E9
ultrasound system had a 3D image acquisition system with a low depth sweep box with a 45◦ angle
and a slow acquisition time to scan the volume. Volume acquisition used 3 orthogonal sectional plans
(A, B, C) and started with the sectional image (A), which gave a 2D image showing the longitudinal
view of the carotid arteries and bulb. Images B and C showed the transverse and horizontal axes,
respectively. The volume sweep was recorded as raw data and used for volume calculations. Volume
calculation was made by delineating the plaque contours and with the transverse plane (B) as described
previously [21]. Plaque volume was evaluated in 96 subjects (67 with type 1 diabetes and 29 without
diabetes. Volume plaque was measured as total and mean plaque volume. Total plaque volume was
defined as the sum of all plaque volume, and mean plaque volume is the sum of the mean plaque
volume of each subject.
Atherosclerotic plaques were classified using the well-known five-type classification system
based on visual assessment of echogenicity with vessel lumen and adventitia as reference structures:
Uniformly echolucent, predominantly echolucent, uniformly echogenic, predominantly echogenic and
extensively calcified plaques [19]. We additionally reclassified individuals into 4 clinical categories that
have been shown to be useful in terms of future outcomes [16]: Echolucent (lipid- and haemorrhage-rich
plaques), mixed (when patients had both echolucent and echo-rich plaques), echogenic (fibrotic
or fibro-fatty plaque); and extensively calcified plaques (echo-shadowing from calcifications) as
previously described [9]. This classification has been validated against histopathology [9,22] and grey
scale medium measured on ultrasound images [23]. The arterial territories explored included the
common and internal carotid territories and the bifurcation from the left and right carotid arteries.
All participants in the study underwent the same carotid ultrasound examination, and all measures
and ultrasound studies were assessed at each participating hospital by the same researcher.
The Local Ethics Committee of both participating centers approved the protocol (PI11/11 and
PI-13-095) in accordance with the Declaration of Helsinki, and all participants signed informed
consent forms.
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2.3. Statistical Analysis
The descriptive statistics of the mean (standard deviation) or median [interquartile range] were
estimated for quantitative variables with a normal or non-normal distribution, respectively. For the
qualitative variables, absolute and relative frequencies were used. Normally distributed data were
analyzed using the Shapiro–Wilk test. The differences between groups were assessed by Student’s test,
analysis of variance or Mann–Whitney test, and Kruskal–Wallis test depending on the distributions
of the quantitative variables. The significance of the differences in qualitative variables was assessed
by Chi-squared test or Fisher’s exact test. A conditional logistic regression model was performed to
study the echogenic plaque and its association with other variables. All variables of the bivariate
analysis with a p-value < 0.2 were used. Only the main effects with a significant contribution to the
final model according to the likelihood ratio test were included in the final model. Goodness of fit
logistic model assumptions were evaluated using the Hosmer–Lemeshow test. Statistical significance
was established at a p-value < 0.05. Data management and analyses were performed with the free
software environment R version 3.3.1 and SPSS software (version 22, SPSS, Chicago, IL, USA).
3. Results
Clinical characteristics of the 174 subjects with carotid plaque included in this study are presented
in Table 1. Patients with type 1 diabetes exhibited an increased prevalence of hypertension and
dyslipidaemia. Among them, up to 60 (56.1%) had diabetic retinopathy. The duration of diabetes
was 24.7 (±12) years. In addition, 76 (71%) patients were under statin treatment, and 53 (49.5%) were
under antiplatelet treatment. Patients with type 1 diabetes also exhibited reduced waist circumference,
diastolic blood pressure, and plasma triglyceride, total cholesterol and low-density lipoprotein (LDL)
cholesterol concentrations compared with the non-diabetic group. Moreover, patients with type 1
diabetes exhibited increased systolic blood pressure, heart rate, and high-density lipoprotein (HDL)
cholesterol concentrations compared with the group of subjects without diabetes (Table 1).
Table 1. Baseline characteristics of the participants.
Non-Diabetic Group
(n = 67)
Type 1 Diabetes
(n = 107) p-Value
Age, years 52.6 (9.13) 54 (9.8) 0.351
Sex, women, n (%) 28 (41.8%) 53 (49.5%) 0.401
Race, non-Caucasian, n (%) 2 (3%) 0 (0%) 0.147
Tobacco exposure, n (%) 35 (53%) 70 (65.4%) 0.144
Antiplatelet treatment, n (%) 3 (10.3%) 53 (49.5%) <0.001
Dyslipidaemia, n (%) 20 (29.9%) 78 (72.9%) <0.001
Hypertension, n (%) 13 (19.4%) 60 (56.1%) <0.001
Systolic blood pressure, mmHg 131 (14.2) 137 (18) 0.010
Diastolic blood pressure, mmHg 79.6 (8) 74.7 (11.6) 0.001
Statin treatment, n (%) 8 (11.9%) 76 (71%) <0.001
Heart rate, beats/min 71 (11.1) 76.8 (11.9) 0.002
Body mass index, kg/m2 27.8 [25; 30.3] 26.4 [24.3; 29.6] 0.124
Waist, cm 99.6 (12.8) 92.9 (12.7) 0.001
HbA1c, % 5.5 [5.3; 5.7] 7.6 [7.15; 8.15] <0.001
HbA1c, mmol/mol 36.6 [34; 39] 60 [54; 65.5] <0.001
Total cholesterol, mg/dL 203 [185; 228] 173 [155; 198] <0.001
HDL cholesterol, mg/dL 54 [46; 63] 59 [52; 70] 0.005
LDL cholesterol, mg/dL 124 [112; 148] 97.4 [80.6; 113] <0.001
Triglycerides, mg/dL 99 [65; 142] 71 [57; 90] 0.001
Creatinine, mg/dL 0.81 [0.7; 0.9] 0.79 [0.7; 0.9] 0.166
GFR, mL/min/1.73 m2 97.9 [85.6; 105] 96.1 [88.3; 105] 0.899
Diabetes duration, years - 24.7 (12) -
Plaque 0.581
One plaque 35 (52.2%) 50 (46.7%)
Multiple plaques (≥2) 32 (47.8%) 57 (53.3%)
Data are mean (SD) or median [interquartile range] or n (%). GFR, Glomerular filtration rate estimate based on the
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation; HDL, high-density lipoprotein; HDL,
low-density lipoprotein.
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3.1. Ultrasound Examination
No differences were observed in the proportion of subjects with either one or more carotid
plaque between patients with type 1 diabetes and subjects without diabetes (Table 1). Regarding
plaque echogenicity, differences were observed between study groups (p = 0.001) (Figure 1A).
The proportion of patients with type 1 diabetes who had only echolucent, i.e., lipid-rich plaques, was
reduced in patients with type 1 diabetes compared with subjects without diabetes (48.6% vs. 73.1%,
respectively). In contrast, the proportion of patients with only echogenic plaques, i.e., those who
contain more calcification and fibrous tissue, was increased in the group of patients with type 1 diabetes
(25.2% vs. 7.5%). In addition, the proportion of patients with at least one echogenic plaque was
increased in patients with type 1 diabetes compared with subjects without diabetes (49.5% vs. 26.9%,
p = 0.005) (Figure 1B). When stratifying the groups by sex, differences in the proportion of patients
with echogenic plaques were observed. In subjects without diabetes, the proportion of those with
echogenic plaques was increased in men (12.8% vs. 0%). In the group of patients with type 1 diabetes
no differences were found between sexes (24.1% in men and 26.4% in women).
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Figure 1. Atherosclerotic plaque type. (A) Proportion of patients with different types of atherosclerotic
plaques (only echolucent, only echogenic, mixed of echolucent and echogenic plaques, and calcified
with or without another plaque type). (B) Proportion of patients with different types of atherosclerotic
plaques (at least one echolucent plaque, at least one echogenic plaque, and at least one calcified plaque).
Finally, no differences were noted in the proportion of patients with mixed plaque types
(echolucent and echogenic) between the study groups (16.8% vs. 17.9%). Additionally, the proportion
of patients with at least one extensively calcified plaque was increased in patients with type 1 diabetes
compared with subjects without diabetes (9.4% vs. 1.5%) (Figure 1B). None of the study subjects had
high-grade (>50%) carotid artery stenosis.
3.2. Me surements of the Plaque Volume
Plaque volume was assessed in 96 subjects; 67 type 1 diabetes patients and 29 control subjects.
There were no differences of total plaque volume between subjects with and without diabetes, median
[IQR], (60 [30; 130] mm3 vs. 50 [20; 80] mm3; p = 0.260). However, the mean plaque volume was higher
in type 1 diabetes patients compared to control subjects (40 [30; 70] mm3 vs. 30 [20; 40] mm3; p = 0.028).
On the other hand, plaque volume (total and mean) were higher in individuals with echogenic plaque
compared with individuals with non-echogenic plaque 100 [60; 160] mm3 vs. 40 [20; 69] mm3; p < 0.001
and 55 [34.2; 80] mm3 vs. 30 [20; 50] mm3; p = 0.003, respectively).
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3.3. Characteristics of Patients with Echogenic Plaques
Seventy-one study subjects exhibited echogenic plaques (including those with or without type 1
diabetes). Among them, up to 53 (74.6%) had type 1 diabetes and up to 41 (57.7%) were under
statin treatment. Subjects with echogenic plaques were older, exhibited an increased frequency of
hypertension and dyslipidaemia, had higher systolic blood pressure and were more frequently under
antiplatelet treatment. On the other hand, total and LDL cholesterol concentrations were reduced in
those patients with echogenic plaques compared with the group without echogenic plaques. Finally,
the proportion of patients with more than one plaque was increased in the group of subjects with
echogenic plaques (Table A1 in Appendix A).
3.4. Logistic Regression Model of Echogenic Plaques
The multiple regression model was constructed using the candidate parameters identified in
the bivariate analysis and the clinically relevant variables to explain the risk of having echogenic
plaques. The model for having echogenic plaques vs. not having echogenic plaques revealed that the
variables associated with the presence of echogenic plaques were older age (OR = 1.06; p = 0.002) and
type 1 diabetes (OR = 2.28; p = 0.026); this model had a good discriminatory ability (AUCROC = 0.73;
p < 0.001) (Table 2).
Table 2. Logistic regression model for the presence of any echogenic plaques.
Presence of any Echogenic Plaque vs. No Echogenic Plaque a
Odds Ratio 95% CI p
Age 1.062 1.023–1.103 0.002
Sex, women 0.539 0.272–1.068 0.076
BMI 0.949 0.872–1.032 0.221
Diabetes 2.276 1.104–4.690 0.026
sBP 1.019 0.998–1.040 0.075
BMI, body mass index; sBP, systolic blood pressure. a The logistic model showed a good discrimination with an
AUC of 0.73 (95% CI: [0.65–0.80] and no significant lack of calibration (Hosmer–Lemeshow test p-value = 0.21).
4. Discussion
In the present study that included a large sample of patients with type 1 diabetes and subjects
without diabetes, all of whom had at least one carotid atherosclerotic plaque, we report for the first
time that the ultrasound tissue characterization of carotid plaques differs between patients with type 1
diabetes and subjects without diabetes. The results obtained show that the proportion of subjects with
echogenic or extensively calcified plaques is increased in patients with type 1 diabetes compared with
subjects without diabetes, whereas the proportion of echolucent plaques is lower in the former.
In the general population, non-invasive measures of subclinical atherosclerosis, such as CAC
burden and atherosclerotic plaque presence and burden in the carotid arteries, are features associated
with an increased risk of CV events [4,8,12,13]. In addition, plaque characteristics are associated with
the future risk of CV events. Regarding carotid plaques, ultrasonographic plaque characterization
studies performed in the general population have demonstrated that echolucent plaques are
independently associated with an increased risk of cerebrovascular and other CV events [24] in
symptomatic patients with stenotic plaques (≥50%) [15] and those with non-stenotic plaques [25].
On the other hand, plaque volume, as well as the number of atherosclerotic plaques (i.e., plaque
burden), have both been associated with an increased risk of future CV events [26]. First, in our
study, the mean plaque volume in type 1 diabetic subjects was higher, although this preliminary
finding should be interpreted with caution as the number of subjects is quite low. This prevented
us from further statistical work-up using these data. Interestingly, the proportion of patients with
more than one plaque was increased in the group of subjects with echogenic plaques. In concordance
with this finding, these patients had a higher total plaque volume than the non-echogenic group.
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Thus, the presence of echogenic plaques in a given patient is associated with an increased burden
of atherosclerosis (total number and volume of plaques). Therefore, future studies should address
the issue of whether subjects with echogenic plaques, especially if they have type 1 diabetes, are
at a higher risk of cardiovascular events than those with echolucent plaques. Additionally, in the
general population, carotid plaque calcification, which is defined as that with an acoustic shadowing,
is a strong and an independent predictor of vascular events in asymptomatic subjects [11,27]. In
type 2 diabetes, the presence of both echolucent [16,17,28] and echogenic plaques [12,18] is also
independently associated with an increased risk of CV events. In contrast to echolucent plaques, which
are lipid rich, echogenic plaques contain more calcification and fibrous tissue. In the general population
and patients with type 2 diabetes carotid plaque calcification, as assessed by computed tomography, is
independently associated with a future risk of cardiovascular events [12]. Not only the presence of
calcium in the atherosclerotic plaque but also the pattern of the calcium depots has been suggested to
be involved in the vulnerability of the atherosclerotic lesion. In this sense, microcalcification patterns,
i.e., spotty calcium depots, are associated with vulnerability of coronary atherosclerotic plaques in
contrast to extensive calcifications, which are associated with stable plaques [29–31]. These findings
suggest that microcalcification may increase wall stress in the fibrous cap, resulting in plaque instability
as a characteristic of vulnerable plaques [31,32]. In the present study, presence and characteristics
of carotid plaques were evaluated with carotid B-mode ultrasound. Actually, as contrast-enhanced
modalities that are the best method to analyze the characteristics of vulnerable atherosclerotic plaques
such as inflammation, intraplaque haemorrhage and ulceration, the use of this ultrasound method
might have clearly improved the adequate characterization of carotid atherosclerotic plaques of type
1 diabetic patients; unfortunately, this is a rather time-consuming and expensive procedure that we
could not use in the current study.
Few studies have analyzed the presence and tissue characteristics of atherosclerotic plaques
in type 1 diabetes. Atherosclerotic CV disease is the leading cause of death in people with type 1
diabetes whose risk of CV disease is two- to seven-fold increased and not completely accounted for
by traditional CV risk factors [33]. For example, women exhibit a two-fold increased risk of fatal
and nonfatal vascular events compared with men with type 1 diabetes [1]. Our group has recently
described an increased proportion and burden of carotid plaques in type 1 diabetic patients without
CV events compared with subjects without diabetes [7]. In this group of patients, the presence of
advanced stages of diabetic retinopathy is independently associated with the presence and the burden
of subclinical carotid atherosclerosis. Plaque tissue characteristics in patients with type 1 diabetes
have been mainly studied in coronary arteries by computed tomography. Studies demonstrate that
diabetes is associated with an increased prevalence of any degree of calcification compared with
control subjects [32]. Moreover, coronary artery calcification is greatly increased in women, and the
gender difference in calcification observed in the general population is lost in subjects with type 1
diabetes [34,35]. In addition, Djaberi et al., used multislice computed tomography to assess coronary
atherosclerosis and found no differences in average CAC scores and the prevalence of coronary
atherosclerosis between asymptomatic patients with type 1 and type 2 diabetes, with the exception of
an increased percentage of noncalcified plaques in patients with type 2 diabetes [36].
To the best of our knowledge, no studies to date have analyzed the ultrasound characteristics of
carotid plaques in patients with type 1 diabetes. The results obtained in the present study demonstrated
that the proportion of subjects with echogenic plaques is increased in patients with type 1 diabetes
compared with subjects without diabetes without differences between gender in the proportion
of subjects who have echogenic plaques. These results point to a greater effect of calcification in
women compared with men given that echogenic plaques contain more calcified tissue compared
with echolucent plaques. These results are similar to those that have described a reduction in the
gender difference in coronary artery calcification given that the prevalence of CAC is similar in men
and women [35]. The analysis performed in the present study to analyze those variables associated
with the risk of having echogenic plaques noted that older age and type 1 diabetes were the only ones
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that were independently associated with the risk of having this type of plaque. However, we must
acknowledge that although we found an association between each of these two variables with the
presence of echogenic plaques, the low number of subjects studied may reduce the chance of finding
an association with other cardiovascular disease-related or unexplored factors. Finally, regarding
extensive plaque calcification, our results demonstrate that the proportion of patients with at least one
extensively calcified plaque was increased in patients with type 1 diabetes compared with subjects
without diabetes, which is similar to the increased coronary artery calcification described in patients
with type 1 diabetes compared with nondiabetic subjects.
In the general population, treatment with statins promotes coronary artery calcification [37].
Few studies have analyzed the effect of statin treatment on calcium content in coronary arteries in
patients with diabetes mellitus. These studies have been performed in patients with type 2 diabetes.
The results indicate that patients who receive statins exhibit an increased degree of calcification as
assessed by CAC compared with those who are not receiving statins; however, the progression of
CAC scores is faster in those who are not receiving statins [38,39]. In this sense, some authors have
suggested that statins render microcalcifications more confluent, which could be associated with a
reduction in vessel wall stress [40]. In fact, patients with diabetes and patients with a previous CV
event are frequently treated with statins given that this treatment decreases the incidence of CV events
in these populations. Our study reported no differences in the plaque type distribution between the
complete series and patients without statin treatment (Figure A1 in Appendix A), or between subjects
under statin treatment with and without echogenic plaques.
Our study has several limitations. First, although we adjusted for risk factors known to be
associated with atherosclerosis, it is possible that some confounding factors exist and were incompletely
accounted for. Second, the cross-sectional design precludes conclusions about causality; therefore,
a larger prospective study is needed to establish the usefulness of plaque type characterization as a
predictive factor for CV events in patients with type 1 diabetes. Finally, an additional limitation is that
only a limited number of patients with echogenic plaques were studied; therefore, larger studies are
warranted as no final conclusions can be drawn from our findings.
5. Conclusions
In summary, our study demonstrates that in the absence of previous CV disease, non-stenotic
carotid plaque ultrasound characteristics differ between patients with type 1 diabetes and subjects
without diabetes. The proportion of echogenic plaques, which comprise calcified tissue, is increased
in patients with type 1 diabetes, and no differences exist in the proportion of subjects with echogenic
plaques between genders. This finding is consistent with the notion that diabetes is associated with
vascular calcification and the loss of gender differences in calcification. Whether the increase in the
proportion of plaques with this ultrasonographic pattern observed in patients with type 1 diabetes will
translate into an increased risk of future cardiovascular events will be determined in the prospective
follow-up of this cohort of patients.
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Appendix A
Table A1. Baseline characteristics of the study group according to the presence of echogenic plaques.
Variable
Non-Echogenic Plaque Echogenic
p-Value Plaque
n = 103 n = 71
Age, years 51.2 (9.22) 56.7 (9.11) <0.001
Sex, women, n (%) 52 (50.5%) 29 (40.8%) 0.272
Race, non Caucasian, n (%) 2 (1.94%) 0 (0.00%) 0.514
Diabetes mellitus type 1, n (%) 54 (52.4%) 53 (74.6%) 0.005
Diabetes duration, years 22.2 (11.8) 27.2 (11.8) 0.030
Tobacco exposure, n (%) 58 (56.9%) 47 (66.2%) 0.281
Hypertension, n (%) 33 (32.0%) 40 (56.3%) 0.002
Dyslipidaemia, n (%) 47 (45.6%) 43 (60.6%) 0.075
BMI, kg/m2 27 [25;29.9] 26.7 [24.2;29.8] 0.424
Waist, cm 96.0 (12.0) 94.5 (14.6) 0.469
Systolic blood pressure, mmHg 132 (17.4) 139 (15.5) 0.004
Diastolic blood pressure, mmHg 76.3 (10.2) 76.9 (11.3) 0.730
Heart rate, beat/min 74.1 (12.8) 75.6 (10.6) 0.391
Antiplatelet treatment, n (%) 23 (29.1%) 33 (57.9%) 0.001
Statin treatment, n (%) 43 (41.7%) 41 (57.7%) 0.055
Glucose, mg/dL 99 [87.5; 140] 127 [88; 211] 0.034
HbA1c, % 6.7 [5.5; 7.6] 7.40 [6.3; 7.9] 0.006
HbA1c, mmol/mol 49.7 [36.6; 60] 57 [45; 63] 0.006
Triglycerides, mg/dL 74 [59; 106] 81 [60.5; 126] 0.313
Total cholesterol, mg/dL 192 [170; 218] 178 [160; 202] 0.016
HDL, mg/dL 58 [49.5; 70] 56 [47.5; 68.5] 0.296
LDL, mg/dL 112 [92.5; 141] 107 [82.5; 120] 0.036
Creatinine, mg/dL 0.8 [0.67; 0.9] 0.79 [0.66; 0.92] 0.756
GFR, mL/min/1.73 m2 97.6 [87.4; 106] 96 [86.8; 104] 0.485
Plaque, n (%)
<0.001One plaque 67 (65%) 18 (25.4%)
Multiple plaques 36 (35%) 53 (74.6%)
Data are mean (SD) or median [interquartile range] or n (%). GFR, Glomerular filtration rate estimate by the
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
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with or without another plaque type), n = 90. 
  
0
20
40
60
80
P
ro
p
o
rt
io
n
 o
f s
u
b
je
c
ts
 (
%
) Control
Type 1 diabetes
EchogenicEcholucent CalcifiedMixed
p= 0.008
Figure A1. Propo tion of patients without statin trea ment with different types of atherosclerotic plaque
(only echolucent, only echogenic, mix d of echoluc nt and echog nic plaques, and calcified with or
without another plaque type), n = 90.
J. Clin. Med. 2019, 8, 424 10 of 12
References
1. Huxley, R.R.; Peters, S.A.; Mishra, G.D.; Woodward, M. Risk of all-cause mortality and vascular events in
women versus men with type 1 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol.
2015, 3, 198–206. [CrossRef]
2. Peters, S.A.; Huxley, R.R.; Woodward, M. Articles Diabetes as a risk factor for stroke in women compared
with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539
strokes. Lancet 2014, 383, 1973–1980. [CrossRef]
3. Stein, J.H.; Korcarz, C.E.; Hurst, R.T.; Lonn, E.; Kendall, C.B.; Mohler, E.R.; Najjar, S.S.; Rembold, C.M.;
Post, W.S. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid
ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus
statement from the American Society of Echocardiography carotid intima-media thickness task force
endorsed by the Society for Vascular Medicine. J. Am. Soc. Echocardiogr. 2008, 21, 93–111. [PubMed]
4. Baber, U.; Mehran, R.; Sartori, A.; Schoos, M.M.; Sillesen, H.; Muntendam, P.; Garcia, M.J.; Gregson, J.;
Pocock, S.; Falk, E.; et al. Prevalence, impact, and predictive value of detecting subclinical coronary and
carotid atherosclerosis in asymptomatic adults. J. Am. Coll. Cardiol. 2015, 65, 1065–1074. [CrossRef]
5. Inaba, Y.; Chen, J.A.; Bergmann, S.R. Carotid plaque, compared with carotid intima-media thickness, more
accurately predicts coronary artery disease events: A meta-analysis. Atherosclerosis 2012, 220, 128–133.
[CrossRef]
6. Catalan, M.; Herreras, Z.; Pinyol, M.; Sala-Vila, A.; Amor, A.J.; de Groot, E.; Gilabert, R.; Ros, E.; Ortega, E.
Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. Nutr. Metab.
Cardiovasc. Dis. 2015, 25, 742–748. [CrossRef] [PubMed]
7. Carbonell, M.; Castelblanco, E.; Valldeperas, X.; Betriu, À.; Traveset, A.; Granado-Casas, M.; Hernández, M.;
Vázquez, F.; Martín, M.; Rubinat, E.; et al. Diabetic retinopathy is associated with the presence and burden of
subclinical carotid atherosclerosis in type 1 diabetes. Cardiovas. Diabetol. 2018, 17, 66. [CrossRef] [PubMed]
8. Grønholdt, M.-L.M. Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the
carotid artery. Arter. Thromb. Vasc. Biol. 1999, 19, 2–13. [CrossRef]
9. Gray-Weale, A.C.; Graham, J.C.; Burnett, J.R.; Byrne, K.; Lusby, R.J. Carotid artery atheroma: Comparison
of preoperative B-mode ultrasound appearance with carotid endarterectomy specimen pathology.
J. Cardiovasc. Surg. 1988, 29, 676–681.
10. Mitchell, C.C.; Stein, J.H.; Cook, T.D.; Salamat, S.; Wang, X.; Varghese, T.; Jackson, D.C.; Sandoval Garcia, C.;
Wilbrand, S.M.; Dempsey, R.J. Histopathological Validation of Grayscale Carotid Plaque Characteristics
Related to Plaque Vulnerability. Ultrasound Med. Biol. 2017, 43, 129–137. [CrossRef]
11. Mathiesen, E.B.; Bønaa, K.H.; Joakimsen, O. Echolucent plaques are associated with high risk of ischemic
cerebrovascular events in carotid stenosis: The tromsø study. Circulation 2001, 103, 2171–2175. [CrossRef]
[PubMed]
12. Grønholdt, M.-L.M.; Nordestgaard, B.G.; Schroeder, T.; Vorstrup, S.; Sillesen, H. Ultrasonic echolucent carotid
plaques predict future strokes. Circulation 2001, 104, 68–73. [CrossRef] [PubMed]
13. Agarwal, S.; Morgan, T.; Herrington, D.M.; Xu, J.; Cox, A.J.; Freedman, B.I.; Carr, J.J.; Bowden, D.W. Coronary
calcium score and prediction of all-cause mortality in diabetes: The diabetes heart study. Diabetes Care 2011,
34, 1219–1224. [CrossRef] [PubMed]
14. Cox, A.J.; Hsu, F.-C.; Agarwal, S.; Freedman, B.I.; Herrington, D.M.; Carr, J.J.; Bowden, D.W. Prediction of
mortality using a multi-bed vascular calcification score in the Diabetes Heart Study. Cardiovasc. Diabetol.
2014, 13, 160. [CrossRef]
15. Allison, M.A.; Hsi, S.; Wassel, C.L.; Morgan, C.; Ix, J.H.; Wright, C.M.; Criqui, M.H. Calcified atherosclerosis
in different vascular beds and the risk of mortality. Arter. Thromb. Vasc. Biol. 2011, 32, 140–146. [CrossRef]
16. Katakami, N.; Takahara, M.; Kaneto, H.; Sakamoto, K.; Yoshiuchi, K.; Irie, Y.; Kubo, F.; Katsura, T.;
Yamasaki, Y.; Kosugi, K.; et al. Ultrasonic tissue characterization of carotid plaque improves the prediction
of cardiovascular events in diabetic patients: A pilot study. Diabetes Care 2012, 35, 2640–2646. [CrossRef]
[PubMed]
17. Irie, Y.; Katakami, N.; Kaneto, H.; Takahara, M.; Nishio, M.; Kasami, R.; Sakamoto, K.; Umayahara, Y.;
Sumitsuji, S.; Ueda, Y.; et al. The utility of ultrasonic tissue characterization of carotid plaque in the
prediction of cardiovascular events in diabetic patients. Atherosclerosis 2013, 230, 399–405. [CrossRef]
J. Clin. Med. 2019, 8, 424 11 of 12
18. Vigili de Kreutzenberg, S.; Fadini, G.P.; Guzzinati, S.; Mazzucato, M.; Volpi, A.; Coracina, A.; Avogaro, A.
Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. Diabetes Care 2015, 38,
1937–1944. [CrossRef]
19. Alonso, N.; Traveset, A.; Rubinat, E.; Ortega, E.; Alcubierre, N.; Sanahuja, J.; Hernández, M.; Betriu, A.;
Jurjo, C.; Fernández, E.; et al. Type 2 diabetes-associated carotid plaque burden is increased in patients with
retinopathy compared to those without retinopathy. Cardiovasc. Diabetol. 2015, 14, 33–39. [CrossRef]
20. Touboul, P.-J.; Hennerici, M.G.; Meairs, S.; Adams, H.; Amarenco, P.; Bornstein, N.; Csiba, L.; Desvarieux, M.;
Ebrahim, S.; Hernandez, R.; et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus
(2004–2006–2011). Cerebrovasc. Dis. 2012, 34, 290–296. [CrossRef]
21. Ludwig, M.; Zielinski, T.; Schremmer, D.; Stumpe, K.O. Reproducibility of 3-dimensional ultrasound readings
of volume of carotid atherosclerotic plaque. Cardiovas. Ultrasound 2008, 26, 42. [CrossRef]
22. European Carotid Plaque Study Group. Carotid Artery Plaque Composition—Relationship to Clinical
Presentation and Ultrasound B-mode Imaging. Eur. J. Vasc. Endovasc. Surg. 1995, 10, 23–30. [CrossRef]
23. Mayor, I.; Momjian, S.; Lalive, P.; Sztajzel, R. Carotid plaque: Comparison between visual and grey-scale
median analysis. Ultrasound Med. Biol. 2003, 29, 961–966. [CrossRef]
24. Larsen, J.R.; Tsunoda, T.; Tuzcu, E.M.; Schoenhagen, P.; Brekke, M.; Arnesen, H.; Hanssen, K.F.; Nissen, S.E.;
Dahl-Jorgensen, K. Intracoronary ultrasound examinations reveal significantly more advanced coronary
atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls. Diab. Vasc.
Dis. Res. 2007, 4, 62–65. [CrossRef] [PubMed]
25. Costacou, T.; Edmundowicz, D.; Prince, C.; Conway, B.; Orchard, T.J. Progression of coronary artery calcium
in type 1 diabetes mellitus. Am. J. Cardiol. 2007, 100, 1543–1547. [CrossRef] [PubMed]
26. Polak, J.F.; Szklo, M.; Kronmal, R.A.; Burke, G.L.; Shea, S.; Zavodni, A.E.; O’Leary, D.H. The value of carotid
artery plaque and intima-media thickness for incident cardiovascular disease: The multi-ethnic study of
atherosclerosis. J. Am. Heart Assoc. 2013, 2, e000087. [CrossRef] [PubMed]
27. Djaberi, R.; Schuijf, J.D.; Boersma, E.; Kroft, L.J.; Pereira, A.M.; Romijn, J.A.; Scholte, A.J.; Jukema, J.W.;
Bax, J.J. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as
assessed by multislice computed tomography. Diabetes Care 2009, 32, 1507–1512. [CrossRef] [PubMed]
28. Zavodni, A.E.H.; Wasserman, B.A.; McClelland, R.L.; Gomes, A.S.; Folsom, A.R.; Polak, J.F.; Lima, J.A.;
Bluemke, D.A. Carotid artery plaque morphology and composition in relation to incident cardiovascular
events: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology 2014, 271, 381–389. [CrossRef]
29. Prabhakaran, S.; Singh, R.; Zhou, X.; Ramas, R.; Sacco, R.L.; Rundek, T. Presence of calcified carotid plaque
predicts vascular events: The Northern Manhattan Study. Atherosclerosis 2007, 195, e197–e201. [CrossRef]
30. Hunt, K.J.; Evans, G.W.; Folsom, A.R.; Sharrett, A.R.; Chambless, L.E.; Tegeler, C.H.; Heiss, G. Acoustic
shadowing on B-mode ultrasound of the carotid artery predicts ischemic stroke: The Atherosclerosis Risk in
Communities (ARIC) study. Stroke 2001, 32, 1120–1126. [CrossRef]
31. Wilson, P.W.; Kauppila, L.I.; O’Donnell, C.J.; Kiel, D.P.; Hannan, M.; Polak, J.M.; Cupples, L.A. Abdominal
aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001, 103,
1529–1534. [CrossRef] [PubMed]
32. Nonin, S.; Iwata, S.; Sugioka, K.; Fujita, S.; Norioka, N.; Ito, A.; Nakagawa, M.; Yoshiyama, M. Plaque surface
irregularity and calcification length within carotid plaque predict secondary events in patients with coronary
artery disease. Atherosclerosis 2017, 256, 29–34. [CrossRef] [PubMed]
33. McClelland, R.L.; Jorgensen, N.W.; Budoff, M.; Budoff, M.; Blaha, M.J.; Post, W.S.; Kronmal, R.A.; Bild, D.E.;
Shea, S.; Liu, K.; et al. 10-year coronary heart disease risk prediction using coronary artery calcium and
traditional risk factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in
the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J. Am. Coll. Cardiol. 2015, 66,
1643–1653. [PubMed]
34. Lin, R.; Chen, S.; Liu, G.; Xue, Y.; Zhao, X. Association between carotid atherosclerotic plaque calcification
and intraplaque hemorrhage A Magnetic Resonance Imaging Study. Arterioscler. Thromb. Vasc. Biol. 2017, 37,
1228–1233. [CrossRef]
35. Beckman, J.A.; Ganz, J.; Creager, M.A.; Ganz, P.; Kinlay, S. Relationship of clinical presentation and
calcification of culprit coronary artery stenoses. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1618–1622.
[CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 424 12 of 12
36. Shemesh, J.; Stroh, C.I.; Tenenbaum, A.; Hod, H.; Boyko, V.; Fisman, E.Z.; Motro, M. Comparison of
coronary calcium in stable angina pectoris and in first acute myocardial infarction utilizing double helical
computerized tomography. Am. J. Cardiol. 1998, 81, 271–275. [CrossRef]
37. Ehara, S. Spotty Calcification typifies the culprit plaque in patients with acute myocardial infarction:
An Intravascular Ultrasound Study. Circulation 2004, 110, 3424–3429. [CrossRef] [PubMed]
38. Maldonado, N.; Kelly-Arnold, A.; Vengrenyuk, Y.; Laudier, D.; Fallon, J.T.; Virmani, R.; Cardoso, L.;
Weinbaum, S. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability:
Potential implications for plaque rupture. Am. J. Physiol. Heart Circ. Physiol. 2012, 303, H619–H628.
[CrossRef]
39. Lee, S.E.; Chang, H.J.; Sung, J.M.; Park, H.B.; Heo, R.; Rizvi, A.; Lin, F.Y.; Kumar, A.; Hadamitzky, M.; Kim, Y.J.;
et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM (Progression of AtheRosclerotic
PlAque DetermIned by Computed TomoGraphic Angiography Imaging) Study. JACC Cardiovasc. Imaging
2018, 11, 1475–1484. [CrossRef]
40. Puri, R.; Libby, P.; Nissen, S.E.; Wolski, K.; Ballantyne, C.M.; Barter, P.J.; Chapman, M.J.; Erbel, R.; Raichlen, J.S.;
Uno, K.; et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma
composition: Insights from SATURN. Eur. Heart J. Cardiovasc. Imaging 2014, 15, 380–388. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
